Archives of Gynecology and Obstetrics

, Volume 285, Issue 3, pp 779–784 | Cite as

HPV L1 capsid protein expression in squamous intraepithelial lesions of cervix uteri and its relevance to disease outcome

  • Soheila Sarmadi
  • Narges Izadi-mood
  • Mojdeh Pourlashkari
  • Fariba Yarandi
  • Sanaz Sanii
Gynecologic Oncology

Abstract

Purpose

The purpose of this study was to investigate the usefulness of immunocytochemical detection of HPV L1 capsid protein expression in predicting the course of cervical intraepithelial neoplasia.

Background

It is known that most of the low grade dysplastic lesions of cervix uteri regress spontaneously and only some will progress to high grade dysplastic lesions. HPV L1 capsid protein represents about 90% of the total protein on the surface of the virus and can be detected in mild to moderate dysplasia and rarely in severe dysplasia.

Methods

Pap smears from 65 women, in whom diagnoses of LSIL (n = 43) and HSIL (n = 22) were made on cytology and histology specimens, were immunocytochemically stained using antibody against HPV L1capsid protein. The results of immunocytochemical analysis were correlated with the outcome during the 24-month follow-up. p value <0.05 was considered significant.

Results

The immunostaining reaction for L1 capsid protein was positive in 28 cases (65.1%) of LSIL while 15 (34.9%) cases of LSIL and all of the 22 cases of HSIL were negative (p < 0.001). After 24 months of follow-up, among the 28 L1-positive LSIL cases, we found a 60.7% (17/28) spontaneous regression rate, whereas in the 15 L1-negative LSIL patients, the regression rate was 33.3% (5/15). Out of the 22 HSIL cases, 13.6% (3/22) had regression.

Conclusion

Our data support that immunocytochemical detection of HPV-L1 protein could present prognostic information about the evolution of early dysplastic cervical lesions and can be useful in predicting their biologic potential.

Keywords

L1 capsid protein Cervical intraepithelial neoplasia Human papilloma virus Pap smear 

Abbreviations

CIN

Cervical intraepithelial neoplasia

HPV

Human papilloma virus

HSIL

High-grade squamous intraepithelial lesion

LSIL

Low-grade squamous intraepithelial lesion

NPV

Negative predictive value

PPV

Positive predictive value

SCC

Squamous cell carcinoma

Notes

Conflict of interest

The authors declare that they have no conflict of interests.

References

  1. 1.
    Karabulut A, Alan T, Ali Ekiz M, Iritaş A, Kesen Z, Yahşi S (2010) Evaluation of cervical screening results in a population at normal risk. Int J Gynaecol Obstet 110:40–42PubMedCrossRefGoogle Scholar
  2. 2.
    Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. N Engl J Med 348:518–527PubMedCrossRefGoogle Scholar
  3. 3.
    Widdice LE, Moscicki AB (2008) Updated guidelines for papanicolaou tests, colposcopy and human papillomavirus testing in adolescents. J Adolesc Heaith 43:S41–S51CrossRefGoogle Scholar
  4. 4.
    Addis IB, Hatch KD, Berek JS (2006) Intraepithelial disease of the cervix, vagina and vulva.In: Berek and Novak’s Gynecology, 14rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 561–599Google Scholar
  5. 5.
    Agorastos T, Miliaras D, Lambropoulos AF, Chrisafi S, Kotsis A, Manthos A, Bontis J (2005) Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol 121:99–103PubMedCrossRefGoogle Scholar
  6. 6.
    Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000: the global picture. Eur J Cancer 37(Suppl 8):S4–S66PubMedCrossRefGoogle Scholar
  7. 7.
    Hoshikawa S, Sano T, Yoshida T, Ito H, Oyama T, Fukuda T (2010) Immunohistological analysis of HPV L1 capsid protein and p16 protein in low-grade dysplastic lesions of the uterine cervix. Pathol Res Pract 206:816–820PubMedCrossRefGoogle Scholar
  8. 8.
    Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ (2008) Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl 10):K29–K41PubMedCrossRefGoogle Scholar
  9. 9.
    Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D (2005) Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11:4717–4723PubMedCrossRefGoogle Scholar
  10. 10.
    Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE (2010) Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 171:155–163PubMedCrossRefGoogle Scholar
  11. 11.
    Kitchener HC, Castle PE, Cox JT (2006) Achievements and limitations of cervical cytology screening. Vaccine 24(Suppl 3):S3/63–S3/70Google Scholar
  12. 12.
    Nucci MR, Castrillon DH, Bai H, Quade BJ, Ince TA, Genest DR, Lee KR, Mutter GL, Crum CP (2003) Biomarkers in diagnostic obstetric and gynecologic pathology: a review. Adv Anat Pathol 10:55–68PubMedCrossRefGoogle Scholar
  13. 13.
    Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, Nakajima T (2008) Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer 114:83–88PubMedCrossRefGoogle Scholar
  14. 14.
    Griesser H, Sander H, Hilfrich R, Moser B, Schenck U (2004) Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol 26:241–245PubMedGoogle Scholar
  15. 15.
    Zhang Q, Kuhn L, Denny LA, De Souza M, Taylor S, Wright TC Jr (2007) Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 120:351–356PubMedCrossRefGoogle Scholar
  16. 16.
    Melsheimer P, Kaul S, Dobeck S, Bastert G (2003) Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 47:124–128PubMedCrossRefGoogle Scholar
  17. 17.
    Safaeian M, Solomon D, Castle PE (2007) Cervical cancer prevention–cervical screening: science in evolution. Obstet Gynecol Clin North Am 34:739–760PubMedCrossRefGoogle Scholar
  18. 18.
    Choi YS, Kang WD, Kim SM, Choi YD, Nam JH, Park CS, Choi HS (2010) Human papillomavirus L1 capsid protein and human papillomavirus type 16 as prognostic markers in cervical intraepithelial neoplasia. Int J Gynecol Cancer 20:288–293PubMedCrossRefGoogle Scholar
  19. 19.
    Lee H, Lee KJ, Jung CK, Hong JH, Lee YS, Choi YJ, Lee KY, Park G (2008) Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol 36:864–867PubMedCrossRefGoogle Scholar
  20. 20.
    Ungureanu C, Socolov D, Anton G, Mihailovici MS, Teleman S, Rom J (2010) Immunocytochemical expression of p16INK4a and HPV L1 capsid proteins as predictive markers of the cervical lesions progression risk. Morphol Embryol 51:497–503Google Scholar
  21. 21.
    Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH (2010) Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 34:1077–1087PubMedCrossRefGoogle Scholar
  22. 22.
    Negri G, Bellisano G, Zannoni GF, Rivasi F, Kasal A, Vittadello F, Antoniazzi S, Faa G, Ambu R, Egarter-Vigl E (2008) p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 32:1715–1720PubMedCrossRefGoogle Scholar
  23. 23.
    von Knebel Doeberitz M (2002) New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38:2229–2242CrossRefGoogle Scholar
  24. 24.
    Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 110:525–541PubMedCrossRefGoogle Scholar
  25. 25.
    Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum Group Members, Bethesda 2001Workshop (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:2114–2119PubMedCrossRefGoogle Scholar
  26. 26.
    Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88–99PubMedCrossRefGoogle Scholar
  27. 27.
    Griesser H, Sander H, Walczak C, Hilfrich RA (2009) HPV vaccine protein L1 predicts disease outcome of high-risk HPV + early squamous dysplastic lesions. Am J Clin Pathol 132:840–845PubMedCrossRefGoogle Scholar
  28. 28.
    Rauber D, Mehlhorn G, Fasching PA, Beckmann MW, Ackermann S (2008) Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol 140:258–262PubMedCrossRefGoogle Scholar
  29. 29.
    Hilfrich R, Hariri J (2008) Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol 30:78–82PubMedGoogle Scholar
  30. 30.
    Yu L, Wang L, Zhong J, Chen S (2010) Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol 118:47–55PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Soheila Sarmadi
    • 1
  • Narges Izadi-mood
    • 1
  • Mojdeh Pourlashkari
    • 1
  • Fariba Yarandi
    • 2
  • Sanaz Sanii
    • 1
  1. 1.Department of PathologyWomen HospitalTehranIran
  2. 2.Department of Gynecology OncologyWomen HospitalTehranIran

Personalised recommendations